Imunon

Yahoo Finance • 19 days ago

IMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift

Results from OVATION 2 Study reinforce IMNN-001 efficacy benefits observed in the clinic and unique mechanism of action, producing key anti-cancer immune cytokines post-treatment Pivotal Phase 3 trial of IMNN-001 underway, with four trial... Full story

Yahoo Finance • 22 days ago

IMUNON to Present New Translational Data of IMNN-001 Supporting Phase 3 Trial of Immunotherapy for Ovarian Cancer at AACR Special Conference in Cancer Research

OVATION 3 pivotal Phase 3 trial is currently advancing IMNN-001, with several patients being treated LAWRENCEVILLE, N.J., Sept. 19, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development wi... Full story

Yahoo Finance • last month

IMUNON to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

LAWRENCEVILLE, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that a pre-recorded presentation from the Company w... Full story

Yahoo Finance • last month

IMUNON regains compliance with Nasdaq minimum bid price listing requirement

* IMUNON (NASDAQ:IMNN [https://seekingalpha.com/symbol/IMNN]) on Thursday said it has regained compliance with the minimum bid price requirement for continued listing on Nasdaq. * As a result, IMUNON common stock will continue uninterr... Full story

Yahoo Finance • last month

IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

LAWRENCEVILLE, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that the Company has regained compliance with the mini... Full story

Yahoo Finance • 2 months ago

IMUNON INC (NASDAQ:IMNN) Reports Mixed Q2 2025 Results with EPS Beat but Stock Decline

IMUNON INC (NASDAQ:IMNN [https://www.chartmill.com/stock/quote/IMNN]) reported its second-quarter 2025 financial results, revealing a mixed reaction from the market despite beating analyst expectations on earnings per share (EPS). The comp... Full story

Yahoo Finance • 2 months ago

IMUNON Reports Second Quarter 2025 Financial Results and Provides Business Update

Stock dividend issued to IMUNON shareholders reflects confidence in clinical programs, long-term growth strategy and dedication to rewarding shareholders First patient dosed in Phase 3 OVATION 3 Study of IMNN-001 for treatment of newly di... Full story

Yahoo Finance • 2 months ago

IMUNON Announces First Patient Dosed in Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

Initiation of additional trial sites and patient enrollment activities ongoing with multiple patients in screening LAWRENCEVILLE, N.J., July 30, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 d... Full story

Yahoo Finance • 2 months ago

IMUNON to Hold Second Quarter 2025 Financial Results and Business Update Conference Call on Tuesday, August 5, 2025

LAWRENCEVILLE, N.J., July 29, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, announces that the Company will host a conference call at 11:00 a... Full story

Yahoo Finance • 2 months ago

Imunon declares $0.15 dividend

* Imunon (NASDAQ:IMNN [https://seekingalpha.com/symbol/IMNN]) declares $0.15/share  dividend [https://seekingalpha.com/pr/20179224-imunon-announces-stock-dividend-boosting-shareholder-value]. * Payable Aug. 21; for shareholders of reco... Full story

Yahoo Finance • 2 months ago

IMUNON Announces Stock Dividend Boosting Shareholder Value

Stock Dividend Reflects Company’s Confidence in its Phase 3 Study, Long-term Growth Potential, and Dedication to Shareholders LAWRENCEVILLE, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company i... Full story

Yahoo Finance • 3 months ago

IMUNON Granted Continued Listing Extension by Nasdaq to Complete Compliance Plan

Management provides Nasdaq Hearing Panel with a comprehensive executable plan for long term compliance LAWRENCEVILLE, N.J., July 15, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development o... Full story

Yahoo Finance • 3 months ago

Imunon receives Nasdaq exception to address listing deficiencies and amends stock plan

Imunon, Inc. (NASDAQ:IMNN), currently trading at $0.52 and with a market capitalization of $11 million, announced Monday that it has been granted an exception by a Nasdaq Hearing Panel to address its non-compliance with continued listing s... Full story

Yahoo Finance • 3 months ago

IMUNON Submits Plan in Consultation with the Exchange to Ensure Compliance with Nasdaq’s Listing Requirement, Anticipates Additional Compliance Period

Imunon, Inc. LAWRENCEVILLE, N.J., June 30, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that, in consultation with The Nasdaq Stoc... Full story

Yahoo Finance • 4 months ago

IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025

ASCO 2025 overall survival data bolster IMNN-001’s potential in advanced ovarian cancer, supported by robust translational results at ESMO Results from OVATION 2 Study reinforce IMNN-001 mechanism of action, producing IL-12 and key anti-c... Full story

Yahoo Finance • 4 months ago

IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™

Clinical Data Highlight PlaCCine’s Six-Month Durability, Temperature Stability, and Manufacturing Advantages Over mRNA Vaccines IMUNON Seeks Strategic Partner for PlaCCine® to Advance Novel Technology and Fund Core Pipeline with Non-Dilut... Full story

Yahoo Finance • 4 months ago

Life Sciences Investor Forum: Now Available for Online Viewing

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Investor Forum, held June 11th and 12th are now availa... Full story

Yahoo Finance • 4 months ago

Life Sciences Investor Forum Agenda Announced for June 11th-12th

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Investor Forum June 11th & 12th. This event is co-hosted by Zacks Sma... Full story

Yahoo Finance • 4 months ago

IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study

Consistent OS Efficacy Benefit Across Multiple Treatment Subgroups Demonstrates IMNN-001’s Ability to Recruit a Powerful Anti-Cancer Immune Response Results, presented simultaneously in oral presentation at ASCO 2025 and in peer-reviewed... Full story

Yahoo Finance • 4 months ago

IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS

Outstanding Phase 2 Results will be discussed at the 2025 ASCO in an Oral Presentation and featured in peer reviewed medical journal Gynecologic Oncology Phase 3 OVATION 3 Study in progress LAWRENCEVILLE, N.J. , June 02, 2025 (GLOBE NE... Full story